Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société VYNE THERAPEUTICS INC.
01/19VYNE THERAPEUTICS : Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Trea..
PU
01/19VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/19VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Tre..
AQ
01/14VYNE THERAPEUTICS : Unaudited Pro Forma Condensed Consolidated Financial Information - For..
PU
01/14VYNE THERAPEUTICS INC. Change in Directors or Principal Officers, Financial Statements..
AQ
01/13Thinking about buying stock in Adagio Therapeutics, Vyne Therapeutics, PetVivo, BTCS In..
PR
01/13VYNE THERAPEUTICS : Divests Topical Minocycline Assets - Form 8-K
PU
01/13VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Completion of Acquisi..
AQ
01/13VYNE Therapeutics Divests Topical Minocycline Assets
AQ
01/05VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
01/03VYNE Therapeutics to Participate at the LifeSci Partners 11th Annual Corporate Access E..
AQ
2021Thinking about buying stock in Del Taco Restaurants, Vyne Therapeutics, Lucid Group, AS..
PR
2021VYNE Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Confer..
AQ
2021VYNE THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
2021VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Up..
PU
2021VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition, Regulation FD Disc..
AQ
2021VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Up..
AQ
2021Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass a..
PU
2021VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Lead BET Inhibitor, VYN201, Demonstrates Improvement in Reducing Fibrotic Tissue Mass a..
AQ
2021VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
AQ
2021Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm..
PU
2021VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm..
AQ
2021VYNE THERAPEUTICS : Announces Formation of Scientific Advisory Board
AQ
2021VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
PU
2021VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
AQ
2021VYNE THERAPEUTICS : to Present at the Cantor Fitzgerald Investment Conference
AQ
2021VYNE THERAPEUTICS : to Present at the H.C. Wainwright Annual Investment Conference
AQ
2021VYNE THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021VYNE THERAPEUTICS : Explanatory Note (Form 8-K)
PU
2021VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Financial Statements ..
AQ
2021VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021VYNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2021VYNE THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Announces New Strate..
PU
2021VYNE THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Results of Operations..
AQ
2021VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strat..
GL
2021VYNE THERAPEUTICS : Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory ..
AQ
2021VYNE THERAPEUTICS INC. : Other Events (form 8-K)
AQ
2021VYNE THERAPEUTICS : Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) i..
AQ
2021VYNE THERAPEUTICS : to Report Second Quarter 2021 Financial Results on August 12, 2021
AQ
2021VYNE THERAPEUTICS : Certificate of Amendment to the Amended and Restated Certificate of In..
PU
2021VYNE THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, ..
AQ
2021VYNE THERAPEUTICS : Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ..
AQ
2021VYNE THERAPEUTICS INC. : Other Events (form 8-K)
AQ
2021VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digi..
GL
2021VYNE THERAPEUTICS : Management Change/Compensation (Form 8-K)
PU
2021VYNE THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021VYNE THERAPEUTICS REPORTS FIRST QUAR : 30 am Eastern Time
PU
2021VYNE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2021VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021VYNE THERAPEUTICS : Reports First Quarter 2021 Financial Results and Provides Business Upd..
AQ
2021VYNE THERAPEUTICS : to Report First Quarter 2021 Financial Results on May 6, 2021
AQ
2021VYNE THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)
AQ
2021VYNE THERAPEUTICS : Investor Relations Presentation
PU
2021VYNE Therapeutics to Present at Upcoming Virtual Investor Conferences
GL
2021VYNE THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)
AQ
2021VYNE THERAPEUTICS : Investor Relations Presentation
PU
2021VYNE THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
2021VYNE THERAPEUTICS INC. : Results of Operations and Financial Condition (form 8-K)
AQ
2021VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update
GL
2021VYNE Therapeutics to Present at the Cowen 41st Annual Health Care Conference
GL
2021VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
2021VYNE THERAPEUTICS : Announces Development Program for FMX114 Combination Topical Gel for M..
AQ
2021VYNE THERAPEUTICS : Investor Relations Presentation
PU
2021VYNE THERAPEUTICS : to Report Financial Results for the Year Ended December 31, 2020 on Ma..
AQ
2021VYNE THERAPEUTICS INC. : Regulation FD Disclosure (form 8-K)
AQ
2021VYNE THERAPEUTICS INC. : Material Modification to Rights of Security Holders, Amendments t..
AQ
2021VYNE THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form..
AQ
2021VYNE THERAPEUTICS : Announces Reverse Stock Split
AQ
2021VYNE THERAPEUTICS : Thinking about buying stock in Artelo Biosciences, Vaxart, Inovio Phar..
PR
2021VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update
GL
2021VYNE THERAPEUTICS : Announces Closing of $50 Million Registered Direct Offering of Common ..
AQ
2021VYNE THERAPEUTICS : Announces Closing of $50 Million Registered Direct Offering of Common ..
AQ
1  2  3Next
Upcoming event on VYNE THERAPEUTICS INC.
03/03/22